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ABSTRACT
Powder aerosols are being considered as treatment
for patients with Cystyic Fibrosis because powders can
deliver amiloride hydrochloride directly to airway sur¬
faces more quickly and easily than is possible when the
drug is administered in solution.  The goals of this
research were: 1) to increase the fraction of res¬
pirable amiloride hydrochloride mass generated, 2) to
remove larger, non-respirable particles from the
aerosol before inhalation, and 3) to assess the effec¬
tiveness of these aerosol generation techniques for de¬
livering amiloride to the lower airway surfaces.  Three
independent variables were tested, each at three lev¬
els: 1) size range of lactose powder flow-aid used to
help disperse the amiloride aggregates 2) ratio of
amiloride to lactose in the capsule, and 3) total mass
of amiloride and lactose in the capsule.  For the
particle size of interest, 0.7 to 3.3 micrometers, all
three independent variables had a significant effect on
the fraction of respirable amiloride hydrochloride mass
generated.  For size range of lactose flow-aid used to
disperse amiloride aggregates, the trend indicated that
smaller lactose particles, <38 um, were most effective.
For ratio of amiloride to lactose, a 1:2 ratio of lac¬
tose flow-aid to amiloride drug was most effective.
For total mass of amiloride and lactose in the capsule,
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INTRODUCTION
Powder aerosols are being considered to deliver
amiloride, or other therapeutic agents, to patients
with CF because they may deliver a relatively large
amount of drug directly to airway surfaces.  Dry
aerosols are of particular importance because they en¬
able delivery of dry amiloride which should remain in
the airway surface liquid longer than a solution of the
same drug.  As a result, higher drug concentrations on
the airway surfaces can be achieved more quickly and
easily than is possible when the drug is administered
in solution.  Further, delivery of less soluble forms
of the drug may lengthen the residence time of an ef¬
fective concentration of drug on airway surfaces.
Because amiloride is a diuretic, a concern is that
the drug will impact in the mouth and throat, be in¬
gested, and induce renal diuresis and vascular volume
depletion.  To minimize ingestion, yet deliver suffi¬
cient drug for a therapeutic airway surface con¬
centration, the aerosol particles must have the appro¬
priate size distribution.  Developing a powder delivery
system that can target conducting airways of the lung
has been difficult because no present method is avail-
able to quantify drug concentrations in distal aiirways.
Even though lung deposition models are helpful to pre¬
dict where particles of any given size may collect, it
is difficult to document the predicted concentration of
particles in targeted lung surfaces.
Particles from 0.5 to 10 um aerodynamic diameter
deposit in the lungs (1); however, due to the decreased
airway diameters in distal conductive airways, deposi¬
tion of 10 % would be optimistic for particles in this
size range (2).  Most particles larger than 6 um aero¬
dynamic diameter will collect in the nose and mouth and
be swallowed (3) thus being of no use in the treatment
of CF airway dysfunction.  Particles <4 um aerodynamic
diameter are of primary interest in this study.
Pulmonary deposition of these particles occurs
primarily by three mechanisms: 1)  inertial impaction
2)  diffusion and 3)  gravitational sedimentation.  For
particles > 3 um, deposition occurs by inertial im¬
paction in the conducting airways; for smaller parti¬
cles that penetrate to distal regions, diffusion may
predominate.
Small particles are bound to surfaces by van der
Waals and electrostatic forces.  The magnitude of these
binding forces depends on the nature of the material.
the shape and the size of the particles, the roughness
of surfaces, relative humidity, duration of particle
contact, and initial contact velocity.  Current theory
cannot predict adhesive forces accurately, even for the
simplest case of a single particle attached to a de¬
fined substrate (4).  To seperate an agglomerate into
constituent particles, sufficient energy must be sup¬
plied to disperse the particles to the point that at¬
tractive forces become negligible.
The goals of the research were 1) to increase the
fraction of respirable amiloride hydrochloride parti¬
cles being generated 2) to remove larger, non-res-
pirable particles from the aerosol before inhalation,
and 3) to assess the effectiveness of these aerosol




To predict particle deposition patterns, control
must be achieved over the rate and volume of inspira¬
tion because these factors play a major role in deter¬
mining the region of particle deposition within the
airways.  The Spinhaler turbo-inhaler from Fisons, Inc.
was selected for this study because it is activated by
the patient's inspiration and automatically synchro¬
nizes the release of drug with the intake of a breath
(5,6).
Air inhaled through the mouth piece of the Spin¬
haler causes vibratory motion of the rotating impeller
(5,6).  The impeller, in turn, imparts energy to the
drug particles causing agglomerated drug in the capsule
to break up and disperse into the inhaled air.
The May multistage liquid impinger was designed
to fractionate viable organisms by size (7).  This
three stage impinger was designed to approximate the
particle collection characteristics of the oropharynx,
tracheobronchial, and alveolar regions of the res¬
piratory system.  At the recommended flow of 55 liters
per minute, 50% of particles greater than 6 um in
diameter, with estimated specific gravity of 1.5, are
expected to collect on the first stage; the corre¬
sponding cut sizes for the second and third stages are
3.3 and 0.7 microns.  Amiloride hydrochloride has a
specific gravity of 1.53.
EXPERIMENTAL DESIGN
The experiments reported here determine the mass
and size distribution of amiloride hydrochloride powder
dispersed by a Spinhaler over 27 experiments.  Three
independent variables were tested each at three levels:
1) size range of lactose powder flow-aid used to help
break up the amiloride aggregates a) <38 um b) 38-53
um c)  53-75 um;  2) the mass ratio of amiloride to
lactose in each capsule  a) 2:1 b) 1:1 c) 1:2;  and 3)
the total mass of the amiloride and lactose in the cap¬
sule  a) 30 mg b) 40 mg c) 50 mg.  In addition to the
three independent variables, data were collected for
chronological experiment number, relative humidity,
chronological Spinhaler number, and chronological ex¬
periment number for each Spinhaler.
Five additional experiments were conducted at the
intermediate level of each variable to determine exper¬
iment reproducibility, and seven impactor experiments
were conducted to evaluate a specially designed parti¬
cle collection device. See figures (1,2,3) for experi¬






Figure 1.  May multistage liquid impinger.
Key:  1. Spinhaler; 2. artificial throat;
3. impaction stages; 4. impingment
liquid.
ri
Figure 2.  May multistage liquid impinger with the
impactor in line.  Key:  1. impactor
Figure 3.  Experimental apparatus.
Key:  1. rotameter
2. to vacuum
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Figure   4.     Impactor
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The amiloride was hand milled to a CMD of 0.96 um
and a GSD of 1.8.  The lactose flow-aid was sieved into
three size fractions 1) < 38 um, 2) 38-53 um, and 3)
53-75 um.
One portion of this research involved design and
evaluation of an impactor to remove drug particles
larger than approximately 4 um aerodynamic diameter as
they left the Spinhaler, see Figures (2,4).  The im¬
pactor was included in the sampling train for the seven
impactor experiments.
The Spinhaler was connected to the May impinger by
glass tubing (3.5 cm) with an approximate 90 degree
bend to simulate the trachea.  The top two stages of
the May impinger were filled with enough double-dis¬
tilled water to maintain wetted impactor surfaces.  The
bottom stage was filled with 8 ml of double distilled
water.  The May impinger was connected to a glass fiber
filter downstream to collect the finest particles.
Air flow was set at 55 Lpm using a calibrated
rotameter.  1.5 mm holes were hand drilled into stan¬
dard #2 gelatin capsules.  Three capsules were filled
with the appropriate quantities of amiloride and lac¬
tose.  Then the capsule was placed in the rotor cup of
the Spinhaler and suction was applied for 3 0 seconds.
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This sequence was repeated for the other two capsules,
for a total collection time of 90 seconds.
Liquid was syringed, then rinsed from each im-
pinger stage into 100 ml flasks.  Residual amiloride in
the Spinhaler and glass throat were rinsed with double
distilled water and also collected.  The mass of
amiloride in each sample was determined by visible
spectrophotometry using the peak absorbtion wavelength
for amiloride of  361 nm. The lower limit of sensitiv¬
ity for the standard curve was 1.0 ug/ml, or an ab-
sorbance of 0.069.
RESULTS
Amiloride that deposited on the third stage of
the May impinger or on the final filter, particles
smaller than 3.3 um diameter, were of primary inter¬
est to this study, as they should be most likely to
collect on airway surfaces.
In chart 1, total mass in capsule in mg, is
plotted against percent amiloride mass on stage
three.  This chart shows that the less amiloride in
the capsule the greater the percent recovery for the
3rd stage.
In chart 2, total mass in capsule in mg, is
plotted against amiloride mass on stage three.  This
chart shows that the more amiloride present per cap¬
sule the more amiloride recovered on stage 3.
In chart 3, amiloride to lactose mass ratio is
plotted against percent amiloride mass on stage
three.  This chart shows that the less amiloride to
lactose per capsule the greater the percent recovery
of amiloride for the 3rd stage.
In chart 4, amiloride to lactose mass ratio is
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plotted against amiloride mass recovered on stage 3.
This chart shows that the more amiloride present in
the capsule the more amiloride recovered on stage 3.
In chart 5, lactose size range in um, is plot¬
ted against percent amiloride mass on stage 3.  This
chart shows that the smaller the lactose particles
the greater the percent recovery for stage 3.
In chart 6, lactose size range, in um, is plot¬
ted against amiloride mass recovered for stage 3.
This chart shows that the smaller the lactose parti¬
cles the greater the mass recovery of amiloride on
stage 3.
In summary the trend showed that to disperse
amiloride into particles 0.7 - 3.3 um, use less
total mass per capsule, use a high ratio of lactose
flow-aid to amiloride drug, and use small lactose
particles in the capsules.  For example, with 10 mg
amiloride in a capsule and the reported combination
of variables;  1.4 mg of amiloride would be de¬
posited in the region of interest.
As shown in table 1, with the impactor in line,
less amiloride is deposited on the 1st and 2nd
stages without affecting 3rd stage deposition.
For other variable data recorded during the
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experiments no clear trends emerged for the amount
of amiloride collected on stage 3.
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Total Mass in Capsule, mg
Chart   1
Percent Amiloride Mass on Stage Three is plotted
against Total Mass of Amiloride in Capsule.























Total Mass in Copsule
Chart   2
Amiloride Mass in Stage Three is plotted against
Total Mass of Amiloride in Capsule.
Standard Deviations are indicated by brackets.
18



































2 to 1 1  to 1
Amiloride to Lactose Ratio
1 to 2
Chart 3
Percent Amiloride Mass on Stage Three is plottedagainst Amiloride to Lactose Ratio.
Standard Deviations are indicated by brackets.
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1  to 1
Amiloride to Lactose Ratio
1 to 2
Chart 4
Amiloride Mass Collected on Stage Three is plotted
against Amiloride to Lactose Ratio.
Standard Deviations are indicated by brackets.
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< 38 38 to 53
Lactose Size Range, Micrometers
53 to 75
Chart 5
Percent Amiloride Mass on Stage Three is plotted
against Lactose Size Range.
Standard Deviations are indicated by brackets.
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< 38 38 to 53 53 to 75
Lactose Size Range, Micrometers
Chart   6
Amiloride Mass Collected on Stage Three is plotted
against Lactose Size Range.
Standard Deviations are indicated by brackets.
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DISCUSSION
The reproducibility study confirmed that the
experimental procedure could be repeated effec¬
tively.  For particles < 3.3 um, all three indepen¬
dent variables had a significant effect on the total
amiloride mass and the percent total amiloride dis¬
persed into this range, p<0.050 for mass, and
p<0.001 for percent.  See Table 2.  These results
suggest that maximum dispersion occurs with 3 0 mg of
amiloride and lactose in a 1:2 ratio and use of <38
um lactose.  No significant interactions were found.
Analysis of variance found that the impactor
significantly reduced the percent recovery for the top
and middle stages, particles > 3.3 um p<0.001, but not
for the bottom stage p>0.429.
Four Spinhalers were used during this work.  After
eleven experiments the amiloride HCL and flow-aid
failed to discharge from the capsules on some trials.
Spinhalers were replaced once they functioned inconsis-
tantly.
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ANALYSIS OF VARIANCE P VALUES
STAGE 1 STAGE a STAGE 3
TOTAL PERCENT AMILORIDE RECOVERED
MASS IN CAPSI11 F
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Using lactose as a flow aid, results indicate
that most amiloride dispersed is >3.3 um and too
large to reach the tracheobronchial region.  The
fraction that is respirable depends on the size of
amiloride particles, the amount of lactose flow-
aid in capsule, the size of lactose particles and
the ratio of amiloride to lactose.  To maximize
dispersion of respirable sizes use small <38 um
size lactose particles, a 2:1 ratio of the flow-
aid to drug, and 30 mg total mass in the capsule.
The impactor can reduce the amount of large parti¬
cles that reach the patient, without significantly
diminishing the amount of particles 0.7 to 3.3 um
that reach the patient.
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FUTURE WORK
test < 30 mg total mass of drug and flow aid per
sule
test higher ratio of flow aid to drug per capsule
- 3:1,4:1,5:1
test < 38 um lactose particles
test impactor with optimized combination of
variables
test with alternate flow aid
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total mass        ratio amiloride       size of lactose SPINHALER
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< 38 8.90 %
< 53 9,50 %
< 75 18.40 %
< 38 7.80 •/.
< 53 9.50 •/.
< 75 7.80 %
< 38 6.70 '/»
< 53 5.60 «
< 75 8.60 %
size of lactose
in microns
< 38 9,00 %
< 53 8.50 '/.
< 75 10,60 */.
< 38 7.60 •/»
< 53 9.90 %
< 75 6,-^0 %
< 38 5.80 %
< 53 6.40 %
< 75 6.60 %
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PERCEHT   PER CAPSULE
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total mass        ratio amilonde       sire of lactose   THROAT
in mq to lactose in microns
< 33 3.10 */.
two to one            < 53 3.00 '/.
< 75 ^.1+0 •/.
< 33 if,SO '/»
30.00          one to one            < 53 3.''tO '/,
< ͣ   75 iv.30 */,
< 38 5.30 %
one to two            ͣͣͣ:. 53 ^.£0 %
< 75 6.<+0 '/.
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two to one             < 53 S. 90 7»
< 75 4-. 10 ͣ/.
< 3S S.iO •/.
4-0.00          one to one            < 53 3.70 *'.
ͣͣ:   75 if. 10 %
ͣ:: 33 6.00 %
one to two            < 53 if.20 '/.
< 75 if.70 '/.
total mass        ratio amiloriae       size of lactose
in mq          in lactose              in microns
< 33 3.ifO •/.
two to one            <   53 3.10 %
< 75 3.00 >'.
< 38 3.SO %
50.00          one to one            < S3 3.00 */.
< 75 if.50 •/,
< 38 5.10 «
one to two            < 53 5.00 '/.




total mass        ratio amiloride       size of lactose  TDP STAGE
in mq to lactose in microns
< 38 71.10 '/.
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< 75 3.10 %
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size of lactose
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< S3 4.70 'U
< 75 4.40 %
PERCENT PER CAPSULE
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total mass        ratio amiloride       size of lactose
in mg to lactose in microns
< 38 2.30 mg
two to one            < 53 S.43 mg
< 75 ^.70 mg
< 38 1. "^7 mg
^0.00          one to one            < 53 1.87 mg
< 75 1.^7 mg
< 38 0.87 mg
one to two            < 53 0.67 mg
< 75 1.03 mg
total mass        ratio amiloride       size of lactose
in mg          in lactose              in microns
< 38 a.90 mg
two to one            < 53 2.73 mg
< 75 3.^0 mg
< 38 1.83 mg
50.00          one to one            < 53 2.^0 mg
< 75 1.43 mg
< 38 0.93 mg
one to two            < 53 0.97 mg
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< 38 ' ͣ.-' 1.17 mg
< 53 0.73 mg
< 75 1.55 mg
< 38 O.i'fO mg
< 53 0.73 mg
< 75 0.77 mg
< 38 0.77 mg
< 53 0»53 mg
< 75 0.57 mg
size of lactose
in microns
< 38 1.10 mg
< 53 1.00 mg
< 75 0.97 mg
< 38 0.93 mg
< 53 0.73 mg
< 75 1.00 mg
< 38 0.80 mg
< 53 0.80 mg
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total mass        ratio amiloride       size of lactose
in mg to lactose in microns
1.53 mg
two to one < 53 1.30 mg
0.97 mg
1.20 mg
40.00 one to one < 53 0.93 mg
0.73 mg
0.87 mg
one to two < 53 0.63 mg
0.57 mg
total mass        ratio amiloride       size of lactose
in mg in lactose in microns
< 38 1.13 mg
two to one           < 53 1.30 mg
< 75 1.07 mg
< 38 1.17 mg
50.00          one to one            < 53 1.13 mg
< 75 1-07 mg
< 38 1-03 ">9
one to two           < 53 0.73 mg
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